New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
07:55 EDTQSII, QSII, RPTP, RPTP, HTWR, HTWR, CVD, CVD, MDVN, MDVN, IDIX, IDIX, ACHN, ACHN, NVS, NVS, ALR, ALR, SNTA, SNTALeerink to host a conference
Global Healthcare Conference 2013 is being held in New York on February 13-14 with webcasted company presentations to begin on February 13 at 8 am; not all company presentations may be webcasted. Webcast Link
News For QSII;ALR;NVS;ACHN;IDIX;MDVN;CVD;HTWR;RPTP;SNTA From The Last 14 Days
Check below for free stories on QSII;ALR;NVS;ACHN;IDIX;MDVN;CVD;HTWR;RPTP;SNTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 9, 2014
06:43 EDTMDVNMedivation upgraded to Outperform from Market Perform at Bernstein
Subscribe for More Information
06:03 EDTACHNStocks with implied volatility above IV index mean; DISH ACHN
Subscribe for More Information
September 8, 2014
09:27 EDTNVSLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:38 EDTNVSMerus Labs acquires Sintrom from Novartis
Subscribe for More Information
07:33 EDTNVSOphthotech achieves $50M milestone under ex-agreement with Novartis for Fovista
Subscribe for More Information
September 7, 2014
17:15 EDTNVSNovartis presents new data on once-daily Ultibro Breezhaler
Subscribe for More Information
September 5, 2014
14:44 EDTACHNAchillion November volatility elevated into expected release of viral data
Subscribe for More Information
05:59 EDTACHNStocks with implied volatility above IV index mean; ACHN MCD
Subscribe for More Information
September 3, 2014
10:00 EDTALROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:09 EDTRPTPRaptor Pharmaceuticals raises dividend by 7% to 20c per share
Subscribe for More Information
06:17 EDTALRAlere downgraded to Sell from Neutral at Goldman
Subscribe for More Information
05:57 EDTACHNStocks with implied volatility top IV index mean; FXE ACHN
Stocks with implied volatility top IV index mean; Euro Currency Trust (FXE) 7, Achillion (ACHN) 120 according to iVolatility.
05:43 EDTNVSNovartis Gilenya data redefining MS treatment goals
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, MA from September 10-13, will add to the growing evidence confirming the importance of redefining treatment goals in multiple sclerosis, or MS. The goal of MS treatment is to have 'no evidence of disease activity' or 'NEDA', which is currently defined as no evidence of relapses, MRI lesions and disability progression. New data to be presented will reinforce the clinical relevance of brain shrinkage and highlight the benefit of including it as a fourth key measure of MS in the definition of NEDA. In addition, other analyses will show that patients treated with Gilenya were more likely to achieve NEDA based on assessment of these four key measures, including MS-related brain shrinkage, than those on placebo. New Gilenya analyses will show how brain shrinkage is associated with future long-term disability progression in patients with MS and that patients with relapsing MS treated with Gilenya had lower rates of brain shrinkage that importantly were sustained over time. The findings will also provide further evidence of the high efficacy of Gilenya on MS disease activity across four key measures.
September 2, 2014
17:28 EDTNVSNovartis heart drug LCZ696 could drive shares to new highs, Barron's says
Subscribe for More Information
17:18 EDTACHNRA Capital Management reports 18.1% passive stake in Achillion
Subscribe for More Information
10:29 EDTNVSHigh option volume stocks
Subscribe for More Information
07:59 EDTNVSElbit Imaging subsidiary announces Gamida Cell completed execution of agreements
Subscribe for More Information
07:28 EDTACHNAchillion price target raised to $15 from $11 at UBS
UBS raised its price target on Achillion to $15 from $11 citing a positive risk/reward from the expected release of viral data this fall. The firm believes the data will be positive and will be used as a catalyst to drive potential M&A interest and keeps its Buy rating on the stock.
07:01 EDTNVSNovartis volatility expected to move on heart failure drug LCZ696 study
Subscribe for More Information
06:21 EDTACHNStocks with implied volatility top IV index mean; CONN ACHN
Stocks with implied volatility top IV index mean; Conn's (CONN) 67, Achillion (ACHN) 111 according to iVolatility.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use